phrykt

SpyGlass Pharma, Inc. (SGP): who owns it and who trades it

As of Nov 16, 2026, SGP insiders reported 7 purchases worth $83.8M in the last 12 months. The largest buyer was RA Capital Healthcare Fund LP (Director), with $59M. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling SpyGlass Pharma

From the latest filings

Overall: more buying than selling. Famous investors mostly sold. Funds and insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SGP

53 funds and institutions reported SGP shares worth $583M at the end of Q2 2026, about 78% of the company. The largest holder is Ra Capital Management, L.P. with 24.0%.

Funds and institutions (13F) 78%Everyone else 22%

10 largest owners, by share of the company

Ra Capital Management, L.P.24.0%
NEA Management Company, LLC22.1%
Sands Capital Alternatives, LLC7.5%
Samsara Biocapital, LLC6.3%
BlackRock, Inc.2.1%
T. Rowe Price Associates2.0%
Vestal Point Capital, LP2.0%
JPMorgan Chase & Co1.9%
Deerfield Management Company, L.P.1.6%
Millennium Management LLC1.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.8.02M23.99%$179MNo change
NEA Management Company, LLC7.39M22.11%$165MNo change
Sands Capital Alternatives, LLC2.50M7.48%$55.7MNo change
Samsara Biocapital, LLC2.11M6.31%$47MNo change
BlackRock, Inc.711,7122.13%$15.8M+392%
T. Rowe Price Associates674,1432.02%$15M-4%
Vestal Point Capital, LP670,0002.00%$14.9M+0%
JPMorgan Chase & Co629,7391.88%$13.6MNew
Deerfield Management Company, L.P.550,0001.65%$12.2MNo change
Millennium Management LLC507,2571.52%$11.3M+8%
Aberdeen Group plc493,0761.47%$11M+124%
Vanguard Capital Management LLC434,4231.30%$9.7M-0%
Geode Capital Management, LLC277,3250.83%$6.2M+119%
Franklin Resources Inc233,4120.70%$5.2M-22%
Affinity Asset Advisors, LLC131,5860.39%$2.9M-47%
State Street Corp117,5610.35%$2.6M+582%
Charles Schwab Investment Management Inc85,6810.26%$1.9M+44%
Sixth Street Partners Management Company, L.P.85,6810.26%$1.9MNew
Northern Trust Corp82,4510.25%$1.8M+295%
Vanguard Portfolio Management LLC75,8120.23%$1.7M+1960%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, SGP insiders reported $83.8M of open-market purchases and $0 of sales.

Purchases, 12 months
$83.8M
7 trades, 5 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Feb 9, 2026
Filed Feb 11, 2026

Purchases and sales by month

$83.8M$83.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Feb 9, 2026RA Capital Healthcare Fund LP +4DirectorPurchase248,034$16.00$4MForm 4
Feb 9, 2026RA Capital Healthcare Fund LP +4DirectorPurchase3.44M$16.00$55.1MForm 4
Feb 9, 2026Ali BehbahaniDirectorPurchase937,500$16.00$15MForm 4
Feb 9, 2026Geoffrey B PardoDirectorPurchase312,500$16.00$5MForm 4
Feb 9, 2026Bilal Arshad KhanDirectorPurchase20,000$16.00$320KForm 4
Feb 9, 2026Bilal Arshad KhanDirectorPurchase115,000$16.00$1.8MForm 4
Feb 9, 2026Kirk G. NielsenDirectorPurchase165,000$16.00$2.6MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
RA Capital Healthcare Fund LPDirector, 10% owner$59M–Feb 9, 2026
Ali BehbahaniDirector, 10% owner$15M–Feb 9, 2026
Geoffrey B PardoDirector$5M–Feb 9, 2026
Kirk G. NielsenDirector$2.6M–Feb 9, 2026
Bilal Arshad KhanDirector$2.2M–Feb 9, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SGP short interest

Low short interest. 3.5% of SGP shares are sold short: about 1 share in 29. Over the last 12 reports the number of shares short went up 35%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.16M SGP shares were sold short, 3.5% of the shares outstanding, down 5.2% from the report before. At the average daily volume of 96,343 shares, buying them all back would take about 12.1 trading days (days to cover).

Shares short, % of all shares

3.47%May 15Oct 304.12%

Days to cover

12.1May 15Oct 3021.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.16M3.47%-5%96,34312.1
Oct 15, 20261.22M3.66%-2%78,21715.7
Sep 30, 20261.25M3.75%+2%176,3587.1
Sep 15, 20261.23M3.68%+12%105,64811.6
Aug 31, 20261.10M3.28%-4%69,54415.8
Aug 14, 20261.14M3.40%-0%74,58815.2
Jul 31, 20261.14M3.41%+1%94,55312.1
Jul 15, 20261.13M3.38%-14%142,3437.9
Jun 30, 20261.31M3.92%+30%238,2715.5
Jun 15, 20261.01M3.03%-12%70,78614.3
May 29, 20261.14M3.42%+33%58,85819.4
May 15, 2026858,5502.57%-3%62,31913.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

SpyGlass Pharma company events

SpyGlass Pharma filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 19, 2026.

  1. Oct 19, 2026AnnouncementSpyGlass Pharma, Inc. issued a press release providing positive interim 4-year data from its first-in-human trial of its Bimatoprost Drug Pad-IOL System. Filing
  2. Oct 1, 2026AnnouncementThe Company entered into a Stock Purchase Agreement with Santen Holdings US, Inc., a California corporation, and Santen Pharmaceutical Co., Ltd., a Japanese Company. Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. May 14, 2026ResultsReleased financial results. Filing
  5. Mar 26, 2026ResultsReleased financial results. Filing
  6. Mar 9, 2026AnnouncementSpyGlass Pharma, Inc. issued a press release providing positive top-line 12-month clinical updates on its innovative Bimatoprost Drug Pad-IOL System Phase 1/2 trial. Filing
  7. Feb 13, 2026LeadershipSpyGlass Pharma, Inc. filed a Registration Statement on Form S-1 (File No. 333-292779) with the Securities and Exchange Commission (as amended, the “ Registration Statement ”). Filing
  8. Feb 9, 2026LeadershipHabib Dable was appointed to the board of directors of SpyGlass Pharma, Inc. on February 5, 2026 in connection with the Company’s initial public offering. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

SpyGlass Pharma financials

Famous investors that hold SGP

1 of the 50 well-known investors we track reported holding SGP in their latest 13F filing. The largest position is Israel Englander's, worth $10.9M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026418,694$10.9M0.0%-17%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about SpyGlass Pharma, Inc. (SGP) stock

Who owns the most SGP stock?

The largest reported owner of SpyGlass Pharma, Inc. (SGP) is Ra Capital Management, L.P., with 24.0% of the company. In total, 53 funds and institutions reported holding SGP at the end of Q2 2026, together about 78% of the shares. See the largest owners.

Are SGP insiders buying or selling?

In the last 12 months, SGP insiders reported 7 open-market purchases worth $83.8M and no sales. The latest trade was on Feb 9, 2026. See every trade.

What is the short interest in SGP?

As of Oct 30, 2026, 1.16M SGP shares were sold short, 3.5% of the shares outstanding, down 5.2% from the report before. At the average daily volume of 96,343 shares, buying them all back would take about 12.1 trading days (days to cover). See the history.

Which famous investors hold SGP?

1 of the 50 well-known investors we track reported SGP in their latest 13F filing, including Israel Englander. The largest position is worth $10.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.